Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00898079 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Start date: October 13, 2003
Phase:
Study type: Observational

This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.

NCT ID: NCT00897637 Completed - Clinical trials for Recurrent Wilms Tumor and Other Childhood Kidney Tumors

Gene Expression Profiles to Categorize Wilms Tumors

Start date: February 2004
Phase: N/A
Study type: Observational

This laboratory study is using gene expression profiling to identify different categories of Wilms tumors. Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.

NCT ID: NCT00897442 Completed - Melanoma Clinical Trials

Collecting Tumor Samples From Patients With Gynecological Tumors

Start date: June 1992
Phase: N/A
Study type: Observational

This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in the study of cancer.

NCT ID: NCT00896454 Completed - Breast Cancer Clinical Trials

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Start date: November 16, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering corrected serum calcium </= 11.5 mg/dL (2.9 millimoles /L) by day 10.

NCT ID: NCT00895362 Completed - Advanced Cancers Clinical Trials

Erlotinib in Combination With Cetuximab

Start date: April 2009
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of Tarceva (erlotinib hydrochloride) that can safely be given in combination with Erbitux (cetuximab). The safety of this drug combination will also be studied.

NCT ID: NCT00895128 Completed - Advanced Cancer Clinical Trials

Study of Erlotinib in Combination With Dasatinib

Start date: April 2009
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of Tarceva (erlotinib hydrochloride) that can be given in combination with Sprycel (dasatinib). The safety of this drug combination will also be studied.

NCT ID: NCT00894894 Completed - Solid Tumors Clinical Trials

Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies

Start date: May 2007
Phase: Phase 1
Study type: Interventional

Multicenter, open-label, dose-ranging study in two parts: maximum tolerated dose (MTD) segment (the first 28-day course of MP 470) followed by long-term safety segment. MTD segment: follows standard oncology phase-I design; within-patient dose level adjustments prohibited; each patient participates in one of three stages: 1. Accelerated Titration Stage 2. Dose Escalation/De-Escalation Stage 3. Dose Confirmation Stage

NCT ID: NCT00894153 Recruiting - Neoplasms Clinical Trials

p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage

Start date: May 2009
Phase: Phase 4
Study type: Interventional

This is multicenter, open-label, randomized, active-controled, phase IV study of local direct intra-tumor injection of rAd-p53 monotherapy, with concurrent chemotherapy , with concurrent radiotherapy, or combination with surgery for treatment of head and neck malignant tumors in advanced stage .

NCT ID: NCT00893555 Completed - Clinical trials for Hematological Malignancy

Pharmacologic Optimization of Voriconazole

VORI911
Start date: April 2009
Phase: Phase 3
Study type: Interventional

The objective of this study proposal is to determine whether pharmacologic optimization of voriconazole by means of therapeutic drug monitoring (TDM) results in improved patient outcomes (efficacy and safety) and is more cost-effective compared to the current standard of care.

NCT ID: NCT00892502 Completed - Multiple Myeloma Clinical Trials

Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?

Bismuth-PBH
Start date: May 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether treatment with Bismuth can reduce the toxicity of chemotherapy and radiotherapy in patients with malignant diseases of the blood.